Article (Scientific journals)
Place des fibrates dans le traitement de patients avec une dyslipidemie atherogene.
Ducobu, J.; Scheen, André; Legat, P. et al.
2009In Revue Médicale de Liège, 64 (10), p. 512-8
Peer reviewed
 

Files


Full Text
200910_07.pdf
Publisher postprint (904.43 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Atherogenic dyslipidemia; Triglycerides; Statin; Metabolic syndrome; Fibrate; Diabetes; Combined therapy
Abstract :
[en] The demography of dyslipidemia has changed towards a more complex atherogenic dyslipidemia involving increased levels of LDL cholesterol, in particular highly atherogenic small dense particles, hypertriglyceridemia and low HDL cholesterol, together with increased levels of markers of inflammation, thrombogenesis and endothelial dysfunction. Statins were shown to significantly lower cardiovascular morbidity and mortality, but treated patients are still left with a high residual risk, in particular for those with metabolic syndrome, type 2 diabetes, or low HDL cholesterol levels. Fibrates have been shown to reduce plasma triglycerides and increase HDL cholesterol, while improving inflammation, thrombogenesis and endothelial dysfunction. Clinical trials with fibrates have demonstrated their potential to reduce cardiovascular morbidity and mortality too, often through other mechanisms than those of statins. Combination trials of statins with fibrates have shown a more complete improvement of lipid profile and risk markers than each class separately. In contrast with gemfibrozil, fenofibrate does not interact significantly with the pharmacokinetics of statins, and its combination with statins has been shown to have a low risk of muscular side-effects or liver toxicity. The ACCORD outcome trial is exploring possible benefits of the combination of fenofibrate with statins on morbidity and mortality of patients with type 2 diabetes.
Disciplines :
Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition
Author, co-author :
Ducobu, J.
Scheen, André  ;  Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Legat, P.
De Backer, G.
Van Gaal, L.
Velkeniers, B.
Kartounian, J.
Maes, Murielle
Hermans, M;  Katholieke Universiteit Brussel - KUB > E n d o c r i n o l o g i e e t N u t r i t i o n ,
Language :
French
Title :
Place des fibrates dans le traitement de patients avec une dyslipidemie atherogene.
Alternative titles :
[en] Place of fibrates for the treatment of patients with atherogenic dyslipidemia
Publication date :
2009
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Hopital de Baviere, Liège, Belgium
Volume :
64
Issue :
10
Pages :
512-8
Peer reviewed :
Peer reviewed
Additional URL :
Available on ORBi :
since 04 December 2009

Statistics


Number of views
326 (10 by ULiège)
Number of downloads
879 (1 by ULiège)

Scopus citations®
 
4
Scopus citations®
without self-citations
0

Bibliography


Similar publications



Contact ORBi